Abacavir Use Linked to Increased Incidence of MACE
By Elana Gotkine HealthDay Reporter
THURSDAY, Aug. 8, 2024 -- For patients with HIV in the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) trial, use of abacavir was associated with an increased incidence of major adverse cardiovascular events (MACE), according to a study presented at AIDS 2024, the 25th International AIDS Conference, held from July 22 to 26 in Munich.
Carl J. Fichtenbaum, M.D., from the University of Cincinnati, and colleagues examined the role of prior and current use of antiretroviral agents (ART) on the development of MACE in a trial involving 7,769 participants aged 40 to 75 years on ART for at least 180 days.
The median duration of ART use was 9.5 years, with variation by country. The researchers found that 22, 86, 49, and 47 percent of participants reported prior exposure to abacavir, tenofovir (TDF), thymidine analogs (AZT/d4T), and protease inhibitors (PIs), respectively. At study entry, 13, 61, 10, and 26 percent were using abacavir, TDF, AZT/d4T, and PIs, respectively. Entry regimens included two nucleoside reverse transcriptase inhibitors (NRTIs) plus a non-NRTI, integrase strand transfer inhibitor, or PI (47, 25, and 19 percent, respectively). Both former and current use of abacavir was associated with a higher incidence of MACE in adjusted analyses including the baseline regimen. No association was seen for former or current use of other ART agents with MACE.
"Former and current use of abacavir was associated with a higher incidence of subsequent major adverse cardiovascular events in the REPRIEVE trial," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2024
Read this next
AI Can Use ECG Images to Define Risk for Cancer Therapy-Linked Cardiac Dysfunction
MONDAY, Sept. 16, 2024 -- For patients undergoing treatment for certain types of cancer, artificial intelligence (AI) can use electrocardiographic (ECG) images to define the risk...
Breast Arterial Calcifications May Be Marker for Future Heart Disease
WEDNESDAY, Sept. 11, 2024 -- Breast arterial calcifications (BAC) identified on mammography are associated with the development of both atherosclerotic cardiovascular disease...
Psychological Illness, CVD Risk Increased for Relatives, Spouses of Cancer Patients
MONDAY, Sept. 9, 2024 -- Cancer diagnosis is associated with an increased risk for psychological illness and cardiovascular disease among first-degree relatives and spouses of...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.